A Phase Ib Safety, Tolerability, and Efficacy Study of Two Days of Oral Split Dose (25/20 mg) Administration of PF 06412562 in Subjects With Advanced Stage Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2019
Price : $35 *
At a glance
- Drugs PF 6412562 (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Adverse reactions
- 30 Jul 2019 Status changed from active, no longer recruiting to completed.
- 16 Apr 2019 Planned End Date changed from 31 Mar 2019 to 31 Dec 2019.
- 16 Apr 2019 Planned primary completion date changed from 31 Mar 2019 to 31 Dec 2019.